Physician profile
Arminder Singh
NPI 1427088202
$27,545.21
in general payments reported to CMS, 2019-2025
65 companies · $3,892 in 2025
The $3,892 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,982 · 2020: $3,696 · 2021: $3,809 · 2022: $3,376 · 2023: $3,845 · 2024: $3,947 · 2025: $3,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,674.03 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,777.78 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $2,706.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $2,164.34 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Amgen INC. | $2,135.51 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $1,920.01 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $1,568.51 | 2019-2023 | |
| Abbvie INC. | $1,459.66 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $1,329.33 | 2019-2025 | Spravato |
| Novo Nordisk INC | $1,176.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $1,002.03 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $932.47 | 2019-2025 | |
| Allergan, INC. | $718.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.39 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Exact Sciences Corporation | $478.05 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $464.72 | 2024-2025 | Voquezna |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arminder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.